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Introduction: Symptoms may persist after the initial phases of COVID-19 infection, 
a phenomenon termed long COVID. Current knowledge on long COVID has been mostly 
derived from test-confirmed and hospitalized COVID-19 patients. Data are required on the 
burden and predictors of long COVID in a broader patient group, which includes both tested 
and untested COVID-19 patients in primary care.
Methods: This is an observational study using data from Platform C19, a quality improvement 
program-derived research database linking primary care electronic health record data (EHR) 
with patient-reported questionnaire information. Participating general practices invited consent-
ing patients aged 18–85 to complete an online questionnaire since 7th August 2020. COVID-19 
self-diagnosis, clinician-diagnosis, testing, and the presence and duration of symptoms were 
assessed via the questionnaire. Patients were considered present with long COVID if they 
reported symptoms lasting ≥4 weeks. EHR and questionnaire data up till 22nd January 2021 
were extracted for analysis. Multivariable regression analyses were conducted comparing 
demographics, clinical characteristics, and presence of symptoms between patients with long 
COVID and patients with shorter symptom duration.
Results: Long COVID was present in 310/3151 (9.8%) patients with self-diagnosed, clinician- 
diagnosed, or test-confirmed COVID-19. Only 106/310 (34.2%) long COVID patients had test- 
confirmed COVID-19. Risk predictors of long COVID were age ≥40 years (adjusted Odds Ratio 
[AdjOR]=1.49 [1.05–2.17]), female sex (adjOR=1.37 [1.02–1.85]), frailty (adjOR=2.39 [1.29– 
4.27]), visit to A&E (adjOR=4.28 [2.31–7.78]), and hospital admission for COVID-19 symp-
toms (adjOR=3.22 [1.77–5.79]). Aches and pain (adjOR=1.70 [1.21–2.39]), appetite loss 
(adjOR=3.15 [1.78–5.92]), confusion and disorientation (adjOR=2.17 [1.57–2.99]), diarrhea 
(adjOR=1.4 [1.03–1.89]), and persistent dry cough (adjOR=2.77 [1.94–3.98]) were symptom 
features statistically more common in long COVID.
Conclusion: This study reports the factors and symptom features predicting long COVID in 
a broad primary care population, including both test-confirmed and the previously missed 
group of COVID-19 patients.
Keywords: SARS-CoV-2, questionnaire, observational study, frailty, chronic diseases
Plain Language Summary
Why was the study done?
Symptoms of COVID-19 may continue after the initial phases of the infection into 
a condition termed long COVID. Most research on long COVID has focused on patients 
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who had received test confirmation for COVID-19 or were hos-
pitalized with the condition. However, many COVID-19 cases 
went undetected due to the shortage of testing in the early phase 
of the pandemic. This study aims to assess the prevalence of long 
COVID, and the patient characteristics and symptoms which can 
predict the development of long COVID in a broader primary 
care population, including both COVID-19 patients identified via 
testing and those who did not receive test confirmation.
What did the researchers do and find?
This study analyzed the data collected within platform C19, 
a research database combining data from routine primary care 
visits and patient-reported information from a questionnaire. 
Patients were considered to have long COVID if they reported 
having symptoms of COVID-19 lasting at least 4 weeks. Factors 
that predicted the development of long COVID were female sex, 
age above 40, being frail, history of a visit to accidents and 
emergency, and admission to the hospital for COVID-19 infec-
tion. The presence of aches and pains, loss of appetite, confusion 
and disorientation, diarrhea, and persistent dry cough indicates 
patients whose symptoms will likely develop long COVID.
What do these results mean?
This study provides new insights on long COVID in a broad 
range of patients in primary care in the UK. These results may 
assist healthcare providers to identify and manage COVID-19 
patients at risk of persisting symptoms.
Introduction
There have been multiple reports of symptoms of COVID- 
19 infection persisting long after the initial phases of the 
infection, a phenomenon termed long COVID or post- 
acute COVID-19.1,2 There is no single agreed definition 
for long COVID. The UK National Institute of Health and 
Care Excellence (NICE)2,3 and the Wellcome Trust 
foundation4 defined long COVID as symptoms lasting 4 
weeks or more since onset, while other definitions include 
a duration cut-off of 12 weeks.5
Long COVID appears to be common, persistent, and 
debilitating, causing a wide range of physiological and 
cognitive disabilities irrespective of patient age and initial 
disease severity.1,6–9 The impact on social well-being10 
highlights the importance of addressing the persisting 
symptoms of COVID-19 infection. The common presenta-
tion of persisting symptoms includes fatigue, breathless-
ness, chest pain, and body aches.9,11,12 While comparison 
is difficult due to the lack of a uniform definition, espe-
cially in the early days of the pandemic, a review by 
Nalbandian et al suggested up to 87.4% of COVID-19 
patients may remain symptomatic months since the initial 
symptom presentation.1 Symptom of COVID-19 infection 
has also been reported to persist one year post-hospital 
discharge.13
Reports of prevalence from a more general patient popu-
lation suggest a much lower prevalence. The UK COVID-19 
Infection Survey produced experimental results showing 
a national estimate of one in five patients who were tested 
positive for COVID-19 were symptomatic 5 weeks into the 
infection, with a further one in ten patients’ symptoms lasted 
beyond 12 weeks as of 16th December 2020.14 In the US, 
telephone interviews of RT-PCR-confirmed symptomatic 
outpatient adults reported 35% having not recovered after 
2–3 weeks, and only 1 in 5 young healthy adults.11
A better understanding of the symptom characteristics 
and the risk predictors for long COVID is needed to identify 
patients at risk of developing the condition. However, current 
data on persisting symptoms of COVID-19 has been mostly 
derived from cases identified via positive test results.7–11,14– 
16 While the exact numbers are not known, estimates sug-
gested that the majority of COVID-19 cases went 
undetected,17,18 likely due to limited testing capacity in the 
early phase of the pandemic. Furthermore, many studies on 
the long-term symptoms of COVID-19 have focused primar-
ily on hospitalized patients.7–9,12,19–23 The full burden of long 
COVID and factors which predict the risk of developing long 
COVID have not been clearly defined in the primary care 
population including the untested patients who may have 
a milder initial disease but may still be at risk of developing 
long COVID.24 Supplementing electronic health data (EHR) 
data with patient-reported information can provide additional 
insight on these previously missed patients with symptoms of 
COVID-19 managed in primary care.
In response to the pandemic, Optimum Patient Care 
(OPC) UK established the COVID-19 Quality Improvement 
(QI) program to help practices identify and manage patients 
affected by COVID-19 and related problems including pre- 
existing chronic diseases. (https://optimumpatientcare.org/ 
covid-qi/). As part of the program, participating general prac-
titioners invite their patients to complete an online question-
naire covering questions on demographics, co-morbid 
conditions, COVID-19 status, symptoms, and testing. 
Platform C19 systematically assimilates extensive EHR data 
with patient-reported outcomes (PROs) through question-
naires in the primary care population, creating a unique plat-
form that enables new analyses and insights on the pandemic.
This study aims to investigate the prevalence, symptom 
features, and demographical and clinical factors which 
predict the development of long COVID within a broader 
primary care population within Platform C19 which 
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includes both test-confirmed COVID-19 patients and 
COVID-19 patients who did not receive test confirmation.
Methods
Study Design and Data Source
This is an observational study using EHR data and patient- 
reported information data stored in Platform C19. EHR 
data is derived from the OPCRD, a de-identified primary 
care database holding records for more than 12 million 
patients from over 800 GP practices across the UK. The 
OPCRD integrates with all UK clinical systems (EMIS, 
TPP SystmOne, InPS Vision, Microtest Evolution) and 
holds a long retrospective period of data extending from 
the conception of summary diagnostic data collection 
(median time in the database of 13 years). The OPCRD 
data is further enriched with routine EHR data linked with 
patient-reported information from GP practices participat-
ing in OPC QI programs. The questionnaire was designed 
via a consensus of experts from the Platform C19 steering 
committee.
Patients aged 18–85 years at the start of the pandemic 
(1st March 2020) from practices participating in the 
COVID-19 QI program were invited by text message 
from the GP to complete an online COVID-19 question-
naire as part of the QI starting from 7th August 2020. 
Patients that have opted out from data-sharing for 
research25 or from receiving text messages were excluded.
De-identified EHR and questionnaire data collected 
from 7th August 2020 up till 22nd January 2021 from all 
patients who responded were included. To prepare data for 
analysis, questionnaire responses and relevant electronic 
medical records were collated, cleaned, and summarized. 
If patients had multiple questionnaires on record only the 
most recent or most complete one was used. Data is stored 
in a secure, enterprise database running SQL-Server 
(Windows Server 2019 Standard (10.0) Version 
15.0.2080.9).
Study Variables
COVID-19 self-diagnosis, clinical diagnosis, and testing 
were ascertained via the questionnaire. Patients were asked 
whether they believed they have had a COVID-19 infec-
tion, whether they had been diagnosed with COVID-19 by 
a healthcare professional, and whether they had been 
tested for COVID-19 and the result of the test. Patients 
with COVID-19 status were split into three categories: 
self-diagnosed but not diagnosed by a clinician or test- 
confirmed, diagnosed by a clinician but not test-confirmed, 
and test-confirmed positive.
The demographic variables extracted from the EHR 
include age, sex, and smoking status. Data on ethnicity 
and BMI were supplemented by the questionnaire. For 
analysis, age was split into an 18–40 year group and an 
age 40+ group. BMI was split into below 30 kg/m2 and 
greater than or equal to 30 kg/m2; the threshold for obesity. 
Smokers were classified as non-smokers, ex-smokers, cur-
rent smokers, or having an unknown smoking status.
The presence of underlying chronic co-morbid diseases 
was extracted from both EHR and questionnaire. Diseases 
investigated were asthma, COPD, diabetes, heart disease 
or heart failure, kidney disease, and any combination of 
these diseases. Frailty was defined as either recorded 
frailty in the EHR or responding to be frail (“you have 
medical problems that limit how active you are, and you 
need help with daily activities and personal care”) in the 
question assessing the level of fitness. Patients were also 
asked if they visited the accident and emergency depart-
ment, if they were admitted to a hospital, and if they were 
admitted to intensive or critical care for their COVID-19 
infection or symptoms. Presence, start date, and end date 
of symptoms typical of COVID-19 since January 2020 
were asked in the questionnaire. The list of questions 
within the questionnaire used for analysis and the list of 
COVID-19 symptoms are available in the Supplementary 
Material.
Outcome Definition
The primary outcome of this study is the presence of long 
COVID based on COVID-19 status and symptom duration 
based on symptom start and end date as reported by the 
patients. Patients were considered to have had long 
COVID if they were self-diagnosed, clinician-diagnosed, 
or test-confirmed for COVID-19 and have symptoms of 
COVID which lasted for more than 4 weeks based on the 
NICE guideline definition for long COVID.3
Statistical Analysis
All analyses were conducted using Rv4.0.3 (R Core team, 
2020). Univariable logistic regression was conducted to 
summarize each demographic and clinical variable indivi-
dually. Multivariable logistic regression models were cre-
ated using all demographic variables, hospital visits for 
COVID-19, frailty, chronic co-morbid conditions, and 
COVID-19 status as predictors and long COVID as the 
response variable in comparison with COVID-19 with <4 
Pragmatic and Observational Research 2021:12                                                                                 https://doi.org/10.2147/POR.S316186                                                                                                                                                                                                                       
DovePress                                                                                                                          
95
Dovepress                                                                                                                                                            Jones et al




































































week symptom duration. Two separate regression models 
were created, one with each underlying co-morbid chronic 
disease entered as separate variables (split condition 
model) and another with the presence of any underlying 
co-morbid chronic disease combined as a single variable 
(combined condition model).
Univariable and multivariable logistic regression analyses 
to compare the symptom features of long COVID and 
COVID-19 with <4 week symptom duration were also con-
ducted. The multivariable regression model for symptom 
comparison included every symptom adjusted for factors 
that significantly predict long COVID from the analysis 
above. Odds ratios were estimated along with 95% confidence 
intervals to evaluate variable influence. There is no allowance 
for multiplicity. Sensitivity analyses were also conducted on 
long COVID using 12 week symptom duration compared to 
COVID-19 with symptoms lasting <12 weeks.
Results
Patient Breakdown
The patient flowchart is presented in Figure 1. 
Questionnaires were sent to 129,978 eligible patients, of 
whom 31,033 (23.9%) responded. COVID-19 was 
reported by 3151/31,033 (10.2%) respondents, of whom 
310/3151 (9.8%) were present with long COVID. Of 
those, 81/310 (26.1%) were self-diagnosed without clini-
cian diagnosis or test confirmation, 123/310 (39.7%) 
received a diagnosis by a clinician but not test confirma-
tion, and 106/310 (34.2%) had test-confirmed COVID-19.
The demographic and clinical characteristics of the 
patients are presented in Table 1.
Univariable Analysis for Risk Predictors 
for Long COVID
A statistically higher proportion of patients who were 
clinician-diagnosed but not test-confirmed had long 
COVID than those who were test-confirmed (39.7% vs 
34.2%; OR = 1.98 [1.47–2.68]) (Supplementary Table 1). 
Conversely, statistically lower proportion of patients who 
self-diagnosed with neither clinician diagnosis nor testing 
had long COVID compared to test-confirmed patients 
(26.1% vs 34.2%; OR = 0.15 [0.11–0.21]).
Patients with long COVID compared to, by all defini-
tions of self-diagnosed, clinically diagnosed and test- 
confirmed, were statistically more likely to be frail (6.8% 
vs 2.8%; OR = 2.51 [1.49–4.04]), be above the age 40 
(83.2% vs 76.7%; OR = 1.51 [1.12–2.08]), and female 
(72.3% vs 64.2%; OR = 1.45 [1.12–1.89]) compared to 
patients with <4 weeks of symptoms. Of the chronic co- 
morbid diseases, COPD, bronchitis or emphysema (7.4% vs 
2.5%; OR = 3.13 [1.89–5.00]) and heart failure or heart 
disease (9.0% vs 5.0%; OR = 1.89 [1.21–2.84]) were statis-
tically more prevalent in patients with long COVID. 
Statistically more patients with long COVID had visited an 
accident and emergency department (10.6% vs 2.2%; OR = 
5.29 [3.11–8.77]), had been admitted to a hospital (9.0% vs 
1.9%; OR = 5.79 [3.38–9.70]), and had been admitted to an 
intensive or critical care unit (1.6% vs 0.5%; OR = 4.07 
[1.30–10.88]) for their COVID-19 infection or symptoms.
Figure 1 Patient flow.
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Sensitivity analysis using 12 week cut-off definition 
showed similar results, other than for admission to intensive 
or critical care for COVID-19 symptoms (Supplementary 
Table 2).
Multivariable Analysis for Predictors for 
Long COVID
Following multivariable adjustment, patients who were only 
self-diagnosed without clinician diagnosis or test-confirmation 
were statistically less likely to have long COVID (adjusted OR 
= 0.16 [0.11–0.22]) than patients with test-confirmed COVID- 
19. Patients who were clinician-diagnosed without test- 
confirmation also remained statistically more at-risk of long 
COVID (adjusted OR = 1.99 [1.44–2.75]) (Table 2).
Frailty (adjusted OR = 2.39 [1.29–4.27]), age above 40 
years (adjusted OR = 1.49 [1.05–2.17]), and female sex 
(adjusted OR = 1.37 [1.02–1.85]) were independently asso-
ciated with long COVID. However, admission to intensive or 
critical care and all co-morbid chronic diseases were no longer 
statistically significant. Similar results were obtained using the 
Table 1 Patient Demographics and Clinical Characteristics
Variablea Long COVID 
n=310
<4 Weeks COVID-19 
n=2841
Age (years) Mean (SD) 52.1 (12.2) 51.4 (39.5)
Median (IQR) 53 (44–60) 52 (40–61)
18 – <40 52 (16.8%) 662 (23.3%)
≥40 258 (83.2%) 2179 (76.7%)
Sex Female 224 (72.3%) 1825 (64.2%)
BMI (kg/m2) <18.5 3 (1%) 33 (1.2%)
18.5–24.9 63 (21.4%) 679 (25.7%)
25–29.9 92 (31.3%) 837 (31.7%)
30–39.9 102 (34.7%) 874 (33.1%)
≥40 34 (11.6%) 219 (8.3%)
Smoking status Current smokers 38 (12.5%) 340 (12.2%)
Ex-smokers 132 (43.3%) 1129 (40.6%)
Never smoked 135 (44.3%) 1310 (47.1%)
Ethnicity White 278 (96.2%) 2162 (91.8%)
Non-White 11 (3.8%) 194 (8.2%)
Frailty No reported 289 (93.2%) 2761 (97.2%)
Reported Frailty 21 (6.8%) 80 (2.8%)
Hospital visits for COVID-19 symptoms or 
infection
Any 51 (16.5%) 101 (3.6%)
Visited A&E 33 (10.6%) 63 (2.2%)
Admitted to hospital 28 (9.0%) 54 (1.9%)
Admitted to intensive Care 5 (1.6%) 13 (0.5%)
Co-morbid diseases CKD 11 (3.5%) 93 (3.3%)
Hypertension 60 (19.4%) 461 (16.2%)
Heart failure 5 (1.6%) 22 (0.8%)
Other heart diseases 26 (8.4%) 137 (4.8%)
Lung Cancer 0 (0%) 0 (0%)
COPD, bronchitis or 
emphysema
23 (7.4%) 71 (2.5%)
Asthma (ever) 72 (23.2%) 566 (19.9%)
Active Asthma 53 (17.1%) 475 (16.7%)
Diabetes 78 (25.2%) 588 (20.7%)
Depression or anxietyb 84 (27.1%) 559 (19.7%)
Notes: Patients were considered to have COVID-19 if they were self-diagnosed, clinician-diagnosed, or test-confirmed for COVID-19. Patients presented with long COVID 
also have symptoms lasting at least 4 weeks. aNumbers are presented as n (%) of valid responses unless specified. bPrior to January 2020. 
Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.
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combined disease multivariable model (Supplementary 
Table 3).
Sensitivity analysis using the 12 weeks cut-off definition 
showed similar results except for ischemic heart failure or 
heart disease (adjusted OR = 1.72 [1.00–2.87]) in the split 
condition model (Supplementary Tables 4 and 5).
Symptom Features of Long COVID
The presence of symptoms in patients with long COVID 
and COVID-19 with shorter symptom duration is pre-
sented in Figure 2. Almost every (95.2%) patients with 
long COVID reported a loss of appetite. Other commonly 
reported symptoms among long COVID patients were 
persistent dry cough (80.3%), chest pain (79.7%), and 
fatigue or tiredness (72.9%). The symptom features of 
long COVID using the 12 week cut-off definition showed 
a similar pattern (Supplementary Figure 1).
Appetite loss (adjusted OR = 3.15 [1.78–5.92]), persis-
tent dry cough (adjusted OR = 2.77 [1.94–3.98]), confu-
sion or disorientation (adjusted OR = 2.17 [1.57–2.99]), 
aches and pain (adjusted OR = 1.70 [1.21–2.39]), and 
diarrhea (adjusted OR = 1.40 [1.03–1.89]) were statisti-
cally more common in patients with long COVID 
(Table 3). Surprisingly, shortness of breath was statistically 
less common (adjusted OR = 0.68 [0.50–0.91]).
The results using the 12 weeks cut-off were similar 
except “fatigue and tiredness” was also statistically less 
common in long COVID patients (adjusted OR = 0.66 
[0.46–0.96]) (Table 3).
Discussion
Prevalence of Long COVID
In this study, we identified long COVID, defined as COVID-19 
with symptoms lasting at least 4 weeks, in nearly one-tenth of 
Table 2 Split Condition Multivariable Model for Risk Predictors for Long COVID
Variable Adjusted OR (95% CI)a
COVID-19 status Test confirmed positive Reference
Clinical diagnosis without test confirmation 1.99 (1.44–2.75)b
Self-diagnosed without test confirmation 0.16 (0.11–0.22)b
Hospital visit for COVID-19 symptoms or infection None Reference
Visited A & E 4.28 (2.31–7.78)b
Admitted to hospital 3.22 (1.77–5.79)b
Admitted to intensive or critical care 1.29 (0.39–3.71)
Underlying chronic co-morbid diseases No disease Reference
Asthma 1.06 (0.76–1.44)
COPD, bronchitis or emphysema 1.53 (0.84–2.72)
Diabetes 1.07 (0.78–1.45)
Ischemic heart disease or heart failure 1.26 (0.75–2.05)
Kidney disease 1.22 (0.56–2.43)
Age 18–40 years Reference
≥40 years 1.49 (1.05–2.17)b
Sex Male Reference
Female 1.37 (1.02–1.85)b
BMI <30 kg/m2 Reference
≥30 kg/m2 1.05 (0.80–1.37)
Smoking status Non-Smoker Reference
Ex-Smoker 1.15 (0.86–1.53)
Current Smoker 1.43 (0.91–2.20)
Unknown 0.73 (0.11–2.55)
Frailty No reported frailty Reference
Reported frailty 2.39 (1.29–4.27)b
Notes: aAdjusted for all demographic variables, hospital visits for COVID-19, frailty, chronic co-morbid conditions, and COVID-19 status; bStatistically significant at p<0.005.
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COVID-19 cases. This is much lower than the rates reported in 
other studies which have been reported to be more than half the 
patient population.13,22 However, this could be due to the 
difference in the method of symptom assessment and patient 
population. The prevalence observed in this study is closer, 
albeit still lower, compared to more similar general populations 
from the UK COVID-19 infection survey and the proportion 
reported in an observational study based on users of the COVID 
Symptom Study mobile application in the UK (13.3%).14,16 As 
the patients in the current study were not limited to test con-
firmed COVID-19 cases, our results may be reflective of the 
prevalence of long COVID in a more general COVID-19 
population. Indeed, only slightly above one-third of long 
COVID cases identified in this study were test-confirmed, 
highlighting the magnitude of the important yet previously 
unquantified population of long COVID patients.
Predictors of Long COVID
Patients who were diagnosed by a clinician but never test- 
confirmed were more likely to have long COVID than 
those who were test-confirmed positive. We speculate 
that this may be due to patients with milder symptoms 
only received examination and testing after their symp-
toms have persisted. Patients who did not receive test 
confirmation may also make up the group of patients 
from the initial phases of the pandemic when testing and 
awareness of long COVID were limited. In contrast, sig-
nificantly fewer self-diagnosed patients who believed 
themselves to be infected, without a clinician diagnosis 
or test confirmation, had long COVID. This may be as 
patients whose COVID-19 symptoms resolved rapidly did 
not feel the need to be checked by a clinician or tested. 
Alternatively, a proportion of these patients may not have 
had COVID-19 infection and this is difficult to assess.
Older age and female sex were independently associated 
with long COVID. Sexual differences in COVID-19 related 
symptomatology and mortality had been widely recognized. 
While male sex had been reported to be associated with 
a higher risk of COVID-19 hospitalization and mortality,26 
studies have reported female sex to be at a higher risk for 
prolonged COVID-19 symptoms.7,8,16,22,23 Biological dif-
ferences could contribute to the difference in symptom 
persisting between sex, though gender differences in symp-
tom reporting behavior may have also played a part.27
Frailty significantly predicted long COVID even after 
adjustment with age and chronic diseases. Frailty was pre-
viously reported in a multicenter cohort of hospitalized elderly 
patients to be a strong predictor for poorer outcomes of 
Figure 2 Presence of symptoms in COVID-19 patients.
Pragmatic and Observational Research 2021:12                                                                                 https://doi.org/10.2147/POR.S316186                                                                                                                                                                                                                       
DovePress                                                                                                                          
99
Dovepress                                                                                                                                                            Jones et al




































































COVID-19 infection.28 The National Institute for Health and 
Care Excellence (NICE) of the UK advised frailty to be 
included as part of the assessment for patients admitted into 
intensive care during the pandemic.29 Awareness of frailty as 
a risk factor for long COVID may be useful for clinicians when 
patients present with new-onset prolonged diverse symptoms 
as reported in the present study.
Patients who visited an emergency department and who 
were admitted to the hospital for COVID-19 symptoms or 
infections were statistically more likely to have long COVID. 
Similar to our observation on COVID-19 status, this may be 
due to the increasing likeliness of patients visiting the hospital 
as their symptoms persisted or due to the higher severity of 
their illness. Admission to intensive or critical care was no 
longer significant following multivariable adjustment, and this 
may have been due to the small numbers.
Symptom Features of Long COVID
Multiple symptoms across different organ systems were com-
mon among our patients, consistent with known information on 
COVID-19 symptomatology.1 Loss of appetite, persistent chest 
pain, persistent dry cough, and fatigue or tiredness were the 
most commonly reported symptoms. The range of symptoms 
observed in this study is similar to that observed by previous 
studies which commonly list symptoms of fatigue, body aches, 
breathlessness, and cough.9,11,12 However, this study further 
compares patients with long COVID to patients with shorter 
symptom duration to investigate the symptoms that can poten-
tially predict if a patient will develop long COVID.
Individually, all symptoms were significantly more 
commonly reported by long COVID patients than 
patients with shorter symptom duration. This is similar 
to the observation in the study using the COVID 
Symptom Study application.16 Following multivariable 
adjustment of the symptoms with each other, several 
symptoms were no longer independently associated 
with long COVID. Additionally, shortness of breath 
and fatigue or tiredness were found to have an inverse 
association with long COVID using the 12 weeks cut- 
off definition. These results may indicate that these 
symptoms were pervasive enough in the acute phase of 
the infection that they were not strong indicators of 
COVID-19 infection which will persist into long 
COVID. Symptoms of aches and pain, appetite loss, 
confusion and disorientation, diarrhea, and persistent 
dry cough were the symptom features that predicted 
long COVID within our patient population. Diarrhea, 
but not fever or dyspnea, has also been previously 
reported to be associated with persistent symptoms 
among hospitalized patients in India.30
Table 3 Multivariable Analysis for Symptom Features Indicative of Long COVID
Symptoms Since January 2020 Adjusted OR (95% CI)a
4 Weeks Definition 12 Weeks Definition
Abdominal pain 1.33 (0.97–1.83) 1.39 (0.99–1.97)
Aches and pain 1.70 (1.21–2.39)b 1.49 (1.02–2.16)b
Appetite loss 3.15 (1.78–5.92)b 2.91 (1.55–5.91)b
Chest pain 1.42 (0.99–2.04) 1.42 (0.96–2.13)
Confusion or disorientation 2.17 (1.57–2.99)b 2.14 (1.52–3.03)b
Diarrhea 1.40 (1.03–1.89)b 1.42 (1.02–1.98)b
Fatigue or tiredness 0.83 (0.59–1.17) 0.66 (0.46–0.96)b
Fever 0.78 (0.58–1.05) 0.88 (0.63–1.22)
Headache 0.98 (0.71–1.34) 0.99 (0.70–1.40)
Loss/change of smell or taste 1.16 (0.84–1.58) 1.13 (0.80–1.58)
Persistent dry cough 2.77 (1.94–3.98)b 3.24 (2.17–4.921)b
Shortness of breath 0.68 (0.50–0.91)b 0.69 (0.50–0.95)b
Notes: aIn comparison with COVID-19 of shorter symptom duration and adjusted with COVID-19 status, Age, Sex, Frailty, and Hospital Visits. bStatistically significant at 
p<0.005.
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To our knowledge, this study is the first to identify and report 
on the scale of long COVID as well as the predicting factors 
and symptom features of long COVID in the primary care 
population and also including those who had not received 
a diagnosis or test confirmation for their symptoms. Due to 
the limited testing during the initial wave of the pandemic, 
most COVID-19 cases would have gone undetected and 
unrecorded in EHRs. This study, therefore, provides a more 
comprehensive picture of long COVID, which includes the 
previously undetected group of long COVID patients.
A previous investigation on persisting symptoms of 
COVID-19, which included untested patients, was conducted 
by Goertz et al.24 However, in contrast to our study, partici-
pants in the study were recruited from online groups of 
patients with persisting symptoms. The current study further 
supplements our knowledge by including a broader popula-
tion of primary care patients utilizing Platform C19’s unique 
linkage to a quality improvement program and access to EHR 
data supplemented with patient-provided information. This 
provides the unique capability to answer research questions 
that are not possible with EHR data or questionnaires alone. 
The utility of patient-reported outcome measures had been 
previously utilized to demonstrate the social and physical 
impact of persisting COVID-19 symptoms.10
Limitations
Similar to other questionnaire studies, this study is prone to 
non-response bias. Patients who respond may not be fully 
representative of the general population. Due to the electronic 
nature of the questionnaire, it is possible that the elderly and 
frail were less likely to respond. The Black, Asian, and ethnic 
minorities are also currently underrepresented among our 
respondents.
The retrospective nature of this study may have intro-
duced a recall bias. Patients whose symptoms lasted longer 
may perceive themselves as having more symptoms. 
Similarly, patients with more symptoms may have reported 
their symptoms to have lasted longer. This might have 
inflated the differences in symptom features between long 
COVID and COVID-19 of shorter duration. Lastly, symptom 
duration depends on patient recall as it is impossible to retro-
spectively confirm the length of COVID-19 related symp-
toms. We are also unable to ascertain whether the reported 
symptoms were present only during the acute phases of the 
infection or if they persisted as long-term symptoms.
Conclusion
This study provides novel insight on the burden and pre-
dictors of long COVID in a broad primary care population, 
which includes the population of previously undetected 
COVID-19 patients who were not clinically diagnosed or 
test-confirmed. These insights will be valuable for the 
identification of care pathways and interventions to sup-
port this patient group.
Long COVID was observed in almost 10% of COVID- 
19 cases and was mostly from the group of patients who 
did not receive test-confirmed COVID-19. Compared to 
test-confirmed COVID-19 patients, patients who were 
diagnosed by a clinician but not test-confirmed were sig-
nificantly more likely to have long COVID. In contrast, 
patients who were self-diagnosed without clinician diag-
nosis nor test confirmation were significantly less likely. 
Older age, female sex, presence of frailty, visit to an A&E 
department, and hospital admission for COVID-19 symp-
toms or infection significantly predicted long COVID. 
Symptoms of aches and pain, appetite loss, confusion 
and disorientation, diarrhea, and persistent dry cough 
were indicative of cases that persisted into long COVID.
Further analyses using data stored within Platform C19 
will look at the correlation between the risk of developing 
long COVID with the number of symptoms as a metric for 
disease severity, patient behavior, and psychological co- 
morbidities. The multi-organ system symptomatology of 
COVID-19 is similar to that observed in functional dis-
orders such as irritable bowel syndrome, fibromyalgia, and 
chronic fatigue syndrome.31 The potential co-morbid link 
between long COVID and functional disorders is 
a potential area for future analysis using Platform C19.
Data collection under the OPC COVID-19 QI program is 
ongoing. Future studies will investigate the long-term clin-
ical outcome of long COVID and its effect on the well-being 
of patients. With the initiation of the vaccination program in 
the UK, questions on vaccination status will be included in 
future versions of the questionnaire. Future research using 
data stored in Platform C19 will analyze the protective 
effects of vaccinations on the development of long COVID.
Data Sharing Statement
Access to the de-identified patient data used in this study 
may be requested via the OPCRD website (https://opcrd. 
co.uk/platform-c19-new-2/) or via the inquiries email 
info@ opcrd.co.uk.
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The OPCRD has received NHS Research Ethics 
Committee (REC) approval to provide anonymized data 
for scientific and medical research since 2010, with its 
most recent approval in 2015 (NHS HRA REC ref: 15/ 
EM/0150). OPCRD is governed by the Anonymized Data 
Ethics and Protocols Transparency (ADEPT) committee 
(ADEPT1720).
OPC quality improvement programs are provided in com-
pliance with the GDPR/Data Protection Act 2018 (Data 
Protection Register Ref: ZA197058) and the NHS Data 
Security and Protection Toolkit (Ref: 8HR85). The protocol 
of Platform C19 was approved by the ADEPT committee on 
18th November 2020 (ADEPT1720). The study was approved 
on 18th November 2020 by the Anonymized Data Ethics and 
Protocols Transparency Committee (Ref: PROTOCOL2286; 
ADEPT ref: ADEPT1720).
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